Pablo Jiménez
@PaulJiL
Followers
458
Following
513
Media
147
Statuses
423
Medical Oncologist. MD MSc. Clinical Research Fellow. The Royal Marsden NHS. Interested in HN,CSCC,SupportCare&Early phase Clinical Trials! Tweets my own.
London, England
Joined May 2011
A Huge Shout out to the #OncoAlertAF 🚨 What we do We do as A Team Thank you all for your support!! Final Meeting of 2025 (1 of 2) Loads of Great Initiatives COMING your way in 2026! #OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD
1
11
21
Dear Colleagues at #SABCS25 Just to let you know that we will be all the Great Science out of San Antonio will be Discussed in February 2026 for the 6th Annual OncoAlert Colloquium 🚨 REGISTER👉 https://t.co/cp9aGU7SyG We started faculty confirmation yesterday and the line up
0
10
13
#ESMOAsia25 🚨JUPITER-02 Final 6-year OS analysis presented! 1L toripalimab + gem/cis in pts with RM-Nasopharyngeal Ca Median OS 64.8 vs 33.7 mo (HR 0.62; p<0.01) Adjusted post-prog IO: 61.0 vs 25.1 mo (HR O.52) Confirms long-term toriGP combo efficacy 👇Updated situation
Still work to do by western regulatory agencies to ensure access to immuno-chemo combos for patients with R/M nasopharyngeal carcinoma Players⛹🏾♂️⛹🏽♀️ toripalimab, tislelizumab, penpulimab, camrelizumab @brunolarvol @BAHNOOfficial @OracleHNCUK @OncoAlert @ttccgroup Among others 🇬🇧
0
5
11
Musk wants to break up the EU. Putin wants a weaker EU. China wants to divide the EU. Trump wants a far-right EU. WE want a STRONGER EU. Are you with us? 🇪🇺🇪🇺🇪🇺
7K
2K
15K
0
0
2
Just published the full manuscript about our meta-analyses on second-event endpoints (EFS2/PRFS2/PFS2) in antiPD(L)1 trials in @jitcancer 47 RCTs. 34,973 patients 🔸In meta-regressions, prior AntiPD(L)1s exposition reduced/delayed subsequent PD events compared with IO-naïve pts
jitc.bmj.com
Background Immune checkpoint inhibitors (ICIs), particularly anti-PD-(L)1s, have transformed cancer care by their extended efficacy, even receiving next-line. Event-free survival 2 (EFS2), progress...
1
0
5
Eradicating cervical cancer is possible! 👇Australia ZERO incidence for the first time among women aged 20-24, thanks to HPV vaccination👏👏 Australia is committed to eliminate cervix ca by 2035 Source @nhmrc
https://t.co/NZU9tuFY7C
@OncoAlert @brunolarvol
#OncoAlertAF
0
1
6
Sensitive and timely call for patient selection and non-reflex NGS testing in patients with sarcoma, applicable to other rare condiditions 🔸Importance of expect centers 🔸Pathology Review 🔸Findings and context by @DrCeSarcoma @jeanyvesblay Dr Sebastien Bauer Link:
0
9
19
Merus will try to design a subcutaneous version of petosentamab If this will be succesfull as sc amivantamab, it would suppose reducing reactions and possibly lessen heavy premedication currently required @OncoAlert @brunolarvol
#MCLA2 #MCLA3 #Liger1 #liger2 #headandneck
0
2
7
Good morning to all the MAGA patriots working overtime in Nigeria, India, Kenya, Pakistan, Russia and Bangladesh. Nothing says “America First” like tweeting from six different continents. 🌍🇺🇸
1K
18K
80K
TRIAL OPEN: Dry Mouth Relief After Radiotherapy. New hope for dry mouth after radiotherapy! The AQUAx2 Study is investigating a gene therapy for xerostomia. Learn more and check eligibility: https://t.co/tuURjrMcVc
#ClinicalTrials #SGC
0
3
3
It's #MouthCancerActionMonth, and checking your mouth is vital - rare cancers often get missed Early detection is crucial. Be Aware Be Specific. If you spot anything unusual, ask your GP or dentist for a specific referral to a specialist. #RareCancer #SalivaryGlandCancer
0
8
6
No clear evidence to support any link between maternal acetaminophen (Tylenol) intake and autism or ADHD in offspring, a new umbrella systematic review @bmj_latest
50
290
861
Still work to do by western regulatory agencies to ensure access to immuno-chemo combos for patients with R/M nasopharyngeal carcinoma Players⛹🏾♂️⛹🏽♀️ toripalimab, tislelizumab, penpulimab, camrelizumab @brunolarvol @BAHNOOfficial @OracleHNCUK @OncoAlert @ttccgroup Among others 🇬🇧
1
4
13